Update on nephrogenic systemic fibrosis: Are we making progress?

International Journal of Dermatology

Volumn 50, Issue 6, 2011, Pages 659-666

  Haemel, Anna K ^a   Sadowski, Elizabeth A ^a   Shafer, Martin M ^b,c   Djamali, Arjang ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

CLINICAL FEATURE; CONTRAST ENHANCEMENT; DRUG CLEARANCE; EXPERIMENTAL MODEL; HISTOPATHOLOGY; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

CONTRAST MEDIA; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; INFLAMMATION; NEPHROGENIC FIBROSING DERMOPATHY; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 79956202059     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04851.x     Document Type: Review

References (48)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
2. Cowper S, LeBoit P, Su L, et al. Fibrosing skin condition among patients with renal disease - United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002; 51: 25-26.
3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
4. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-906.
5. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
6. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.
7. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
8. US Food and Drug Administration. Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. US FDA Public Health Advisory, 2006.
9. Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 2007; 46: 447-452.
10. Laumann A, Miller F, Tuazon J, et al. Nephrogenic systemic fibrosis (NSF): a report of 12 cases from one medical center. 68th Annual Meeting of the American Academy of Dermatology, March 5-10 2010, Miami, FL.
11. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
12. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18: 2164-2173.
13. Idee JM, Port M, Dencausse A, et al. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009; 47: 855-869.
14. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43: 817-828.
15. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 710-712.
16. Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008; 59: 218-224.
17. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and longterm persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273-280.
18. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium-based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66: 230-234.
19. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008; 21: 129-134.
20. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6years. Curr Opin Rheumatol 2003; 15: 785-790.
21. Vorobiov M, Basok A, Tovbin D, et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003; 18: 884-887.
22. Kunnemeyer J, Terborg L, Nowak S, et al. Analysis of the contrast agent Magnevist and its transmetallation products in blood plasma by capillary electrophoresis/electrospray ionization time-of-flight mass spectrometry. Anal Chem 2009; 81: 3600-3607.
23. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 238-249.
24. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248: 807-816.
25. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25: 358.
26. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 2004; 150: 1050-1052.
27. Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
28. Kirsner RS, Eaglstein WH. The wound healing process. Dermatol Clin 1993; 11: 629-640.
29. Mori L, Bellini A, Stacey MA, et al. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 2005; 304: 81-90.
30. Hardonk MJ, Dijkhuis FW, Hulstaert CE, Koudstaal J. Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. J Leukoc Biol 1992; 52: 296-302.
31. Roggin KK, Papa EF, Kurkchubasche AG, Tracy TF Jr. Kupffer cell inactivation delays repair in a rat model of reversible biliary obstruction. J Surg Res 2000; 90: 166-173.
32. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
33. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60: 1508-1518.
34. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009; 44: 74-81.
35. Jakobsen J. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor. Acta Radiol 2008; 49: 616-617.
36. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43: 65-75.
37. Grant D, Johnsen H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naive and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009; 50: 156-169.
38. Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009; 253: 390-398.
39. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008; 27: 955-962.
40. Pietsch H, Jost G, Frenzel T, et al. Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol 2009; Epub ahead of print.
41. Morcos SK. Validity of the animal models for nephrogenic systemic fibrosis. Invest Radiol 2008; 43: 338, author's reply 338.
42. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on longterm retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009; 44: 226-233.
43. Pietsch H, Lengsfeld P, Jost G, et al. Longterm retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur J Radiol 2009 Nov; 61(6): 537-552.
44. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009 Nov; 61(6): 537-552.
45. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology 2009; 250: 371-377.
46. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two US universities. Radiology 2009; 253: 689-696.
47. Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 2009; 16: 897-905.
48. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007; 48: 593-596.